Business
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia,
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus.\nPhiladelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\") and Helix Nanotechnologies Inc. (\"HelixNano\"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune system's power to fight disease, announced today that they have entered into a non-binding memorandum of understanding (the \"MoU\") in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus' proprietary MNA delivery platform.\nSubject to the certain conditions noted in the MoU, Medicus and HelixNano are currently engaged in good faith negotiations with the aim of forming a joint venture (the \"Joint Venture\") for the co-development and commercialization of thermostable mRNA-based vaccines utilizing their respective proprietary technologies.\nIn parallel with such ongoing negotiations, Medicus and HelixNano have formalized their mutual intent to collaborate on the research, development and production of a batch of clinical-grade mRNA vaccine-loaded MNAs (the \"Project\"), which are intended for use in a Phase 1 clinical bridging study to compare the safety and preliminary efficacy of intramuscular injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001, through the proposed Joint Venture.\n\"The potential of combining HelixNano's potent mRNA vaccine platform with our uniquely formulated dissolvable microneedle array (MNA) technology, is designed to unlock next generation vaccination paradigm,\" stated Dr. Raza Bokhari, Executive Chairman & CEO, \"aiming to develop needle-free, thermostable vaccines that could eliminate cold-chain logistics, reduce distribution costs, improve patient access and offer global scale, which could potentially position us at the forefront of ground-breaking opportunities to prevent, rather than treat, infectious diseases. The Company is exploring numerous possibilities offered by microneedle arrays.\"\nThe purpose of the MoU is to memorialize the mutual intention of the parties to proceed with preliminary collaborative effort...